Media ReleasesAirXpanders Inc

View All AirXpanders Inc News

AirXpanders, Appendix 4C - Quarterly Cash Flow Report and Business Update

Highlights for the quarter ended 30 June 2017

• Revenue increased by 474% compared to Q2 2016; driven by 343% unit sales growth
• Unit growth of 145% as compared to Q1 2017
• Revenue contribution from new sites in the United States ahead of plan
• AeroForm® available in more than one hundred (100) hospitals across the US
• Increased average unit selling price (ASP) in US market as compared to Q1 2017
• Cash and short-term investments balance as of 30 June 2017 of US$27.2 million

Palo Alto, CA, United States – AirXpanders, Inc. (ASX:AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today released its Appendix 4C – Quarterly Cash Flow report for the quarter ended 30 June 2017.

For further information please download PDF attached:
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.